Inclusion Criteria:

   - Histologically or cytologically confirmed diagnosis of metastatic Ewing's sarcoma.

   - Patients must have measurable disease defined as lesions that can be measured by
   medical imaging techniques such as CT or MRI. Ascites, pleural fluid, bone marrow
   disease, lesions seen on scan will not be considered measurable.

   - Patients must have metastatic disease.

   - Age 13 years or older

   - Life expectancy of at least 3 months.

   - ECOG performance status of <= 3.

   - Normal hepatic function (Direct bilirubin <1.5mg/dl, SGOT or SGPT <3x upper limit of
   normal).

   - Left Ventricular Ejection fraction of at least 50%.

   - Adequate renal function: Creatinine clearance >= 50 ml/min or Serum creatinine < 1.5 x
   ULN for age.

   - Adequate bone marrow reserve (defined as an absolute peripheral granulocyte count of
   >=1500/mm3, platelet count of >=75,000/mm3); unless bone marrow infiltrated with
   metastatic Ewing's sarcoma; ANC >= 500 and Platelet >= 50,000 mm3.

   - Ability to understand and willing to sign a written informed consent document.

   - Patients of childbearing potential must agree to use an effective method of
   contraception.

Exclusion Criteria:

   - No prior chemotherapy for Ewing's sarcoma; No prior doxorubicin, temozolomide or
   irinotecan.

   - Known hypersensitivity to any of the components of the protocol drugs.

   - Clinically significant unrelated systemic illness (such as serious infections
   requiring active systemic intravenous antibiotic therapy; cardiovascular disease
   [congestive heart failure, recent myocardial infarction, unstable angina, inadequately
   controlled hypertension].

   - No prior history of chronic diarrhea, bowel obstruction, Crohn's disease or ulcerative
   colitis.

   - Pregnant or nursing woman are not included in the study.

   - HIV-positive patients will be excluded from the study due to risk of infection or
   other serious side effects.

   - Other medical, psychiatric or social condition incompatible with study treatment.